Fig. 1From: Radioligand therapy of metastatic castration-resistant prostate cancer: current approachesA 83-year-old patient with castration-resistant prostate cancer (Gleason-Score:9) and an increasing prostate-specific antigen (PSA) level. He had a history of prostatectomy and radiation therapy of prostate bed. The 68Â Ga-PSMA PET scan showed a diffuse bone and bone marrow involvement (a). The PSA and ALP levels prior to the first cycle of Lu-PSMA therapy were 261Â ng/ml and 659Â U/l, respectively. The patient received 2Â cycles of Lu-PSMA and the PSA level decreased continuously during cycles from 261 to 9.0Â ng/ml (8Â weeks after the second cycle). The ALP showed also a decreasing value from 659 to 81Â U/l (8Â weeks after the second cycle). The PSMA-PET (b) 8Â weeks after the second cycle showed a significant response with significant regression of PSMABack to article page